Possibility to therapeutically exploit RGPR-p117 as a target in cancer cells.

Authors

Masayoshi Yamaguchi

Published in

Expert opinion on therapeutic targets. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

RGPR-p117 was identified as a transcription factor that binds to the TTGGC(N)₆CC sequence in the promoter region of the regucalcin gene, a tumor suppressor. This article discusses the therapeutic potential of targeting RGPR-p117 in cancer cells.
The cytoplasmic RGPR-p117 moves into the nucleus of cells. Once there, it enhances the transcription of several genes containing a TTGGC motif. Overexpression of RGPR-p117 suppresses the proliferation of cancerous cells and decreases the expression levels of proteins that promote their growth, such as Ras, PI3K, Akt, MAPK, mTOR, p53, Rb, and p21. RGPR-p117 also enhances the regucalcin gene expression, which can prevent and treat carcinogenesis. Increasing RGPR-p117 transcription activity may be a promising approach for gene therapy in cancer cells.
Developing novel therapeutic agents that target the RGPR-p117 gene and applying gene therapy are significant and novel cancer treatment strategies. Targeting the RGPR-p117 nuclear translocation pathway may be a new way to suppress cancer. RGPR-p117 shows promise as an effective cancer therapy. However, all of these findings are from in vitro studies. Further in vivo studies and clinical trials are needed, as are solutions to problems, including cancer burden and the need for new targets.

PMID:
42464700
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.